EUVIMEDEUVIMED entdecken
Multizentrische Studie

Multicenter study evaluating target attainment of anti‐Factor Xa levels using various enoxaparin prophylactic dosing practices in adult trauma patients

Tyler Chanas iD, Gabrielle Gibson iD, Elizabeth Langenstroer iD, David J Herrmann iD, Thomas W Carver iD, Kaitlin Alexander iD, Sai Ho Jason Chui iD, Lisa Rein, Michael Ha iD, Kaylee M Maynard, Kristen Bamberg iD, Mary O'Keefe iD und 5 weitere

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · 2024

DOI: 10.1002/phar.2904 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2024. Verfasst von Tyler Chanas und 16 weiteren Autor:innen. Beteiligte Einrichtung: ECU Health Medical Center, Greenville, North Carolina, USA. Hauptthemen laut MEDLINE: Venous Thromboembolism, Burns. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Study Objective Enoxaparin is standard of care for venous thromboembolism (VTE) prophylaxis in adult trauma patients, but fixed‐dose protocols are suboptimal. Dosing based on body mass index (BMI) or total body weight (TBW) improves target prophylactic anti‐Xa level attainment and reduces VTE rates. A novel strategy using estimated blood volume (EBV) may be more effective based on results of a single‐center study. This study compared BMI‐, TBW‐, EBV‐based, and hybrid enoxaparin dosing strategies at achieving target prophylactic anti‐Factor Xa (anti‐Xa) levels in trauma patients.

Design

Multicenter, retrospective review. Data Source Electronic health records from participating institutions. Patients Adult trauma patients who received enoxaparin twice daily for VTE prophylaxis and had at least one appropriately timed anti‐Xa level (collected 3 to 6 hours after the previous dose after three consecutive doses) from January 2017 through December 2020. Patients were excluded if the hospital‐specific dosing protocol was not followed or if they had thermal burns with > 20% body surface area involvement.

Intervention

Dosing strategy used to determine initial prophylactic dose of enoxaparin.

Measurements

The primary end point was percentage of patients with peak anti‐Xa levels within the target prophylactic range (0.2‐0.4 units/mL). Main Results Nine hospitals enrolled 742 unique patients. The most common dosing strategy was based on BMI (43.0%), followed by EBV (29.0%). Patients dosed using EBV had the highest percentage of target anti‐Xa levels (72.1%). Multiple logistic regression demonstrated EBV‐based dosing was significantly more likely to yield anti‐Xa levels at or above target compared to BMI‐based dosing (adjusted odds ratio (aOR) 3.59, 95% confidence interval (CI) 2.29‐5.62, p < 0.001). EBV‐based dosing was also more likely than hybrid dosing to yield an anti‐Xa level at or above target (aOR 2.30, 95% CI 1.33‐3.98, p = 0.003). Other pairwise comparisons between dosing strategy groups were nonsignificant.

Conclusions

An EBV‐based dosing strategy was associated with higher odds of achieving anti‐Xa level within target range for enoxaparin VTE prophylaxis compared to BMI‐based dosing and may be a preferred method for VTE prophylaxis in adult trauma patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous ThromboembolismBurnsAdultHumansEnoxaparinAnticoagulantsBlood Coagulation Tests

Stichwörter der Autor:innen

blood volumebody mass indexbody weightenoxaparinprophylaxistrauma

Substanzen

EnoxaparinAnticoagulants

Autor:innen und Institutionen

  • ECU Health Medical Center, Greenville, North Carolina, USA.
  • Barnes-Jewish Hospital, St. Louis, Missouri, USA.
  • Froedtert & The Medical College of Wisconsin, Milwaukee, Wisconsin, USA.
  • University of Florida College of Pharmacy, Gainesville, Florida, USA.
  • University of Maryland Medical Center, Baltimore, Maryland, USA.
  • Medical College of Wisconsin, Milwaukee, Wisconsin, USA.

ORCID-Profile: Tyler Chanas, Gabrielle Gibson, Elizabeth Langenstroer, David J Herrmann, Thomas W Carver, Kaitlin Alexander, Sai Ho Jason Chui, Michael Ha, Kristen Bamberg, Mary O'Keefe, Brandon Hobbs, William J Peppard

Zitieren

APA

Chanas, T., Gibson, G., Langenstroer, E., Herrmann, D. J., Carver, T. W., Alexander, K., Chui, S. H. J., Rein, L., Ha, M., Maynard, K. M., Bamberg, K., O'Keefe, M., O'Brien, M., Gonzalez, M. C., Hobbs, B., Pajoumand, M., & Peppard, W. J. (2024). Multicenter study evaluating target attainment of anti‐Factor Xa levels using various enoxaparin prophylactic dosing practices in adult trauma patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. https://doi.org/10.1002/phar.2904

Vancouver

Chanas T, Gibson G, Langenstroer E, Herrmann DJ, Carver TW, Alexander K, et al. Multicenter study evaluating target attainment of anti‐Factor Xa levels using various enoxaparin prophylactic dosing practices in adult trauma patients. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 2024. doi:10.1002/phar.2904

BibTeX
@article{Chanas2024,
  author = {Chanas, Tyler and Gibson, Gabrielle and Langenstroer, Elizabeth and Herrmann, David J and Carver, Thomas W and Alexander, Kaitlin and Chui, Sai Ho Jason and Rein, Lisa and Ha, Michael and Maynard, Kaylee M and Bamberg, Kristen and O'Keefe, Mary and O'Brien, Marisa and Gonzalez, Mariela Cardona and Hobbs, Brandon and Pajoumand, Mehrnaz and Peppard, William J},
  title = {Multicenter study evaluating target attainment of anti‐Factor Xa levels using various enoxaparin prophylactic dosing practices in adult trauma patients},
  journal = {Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy},
  year = {2024},
  doi = {10.1002/phar.2904}
}
Kostenlos starten →